J&J ceases opioid business following $230 million settlement and the deaths of 500,000 Americans | WHAT REALLY HAPPENED

J&J ceases opioid business following $230 million settlement and the deaths of 500,000 Americans

Drug giant Johnson & Johnson (J&J) has agreed to stop selling opioid drugs in the United States following a $230 million settlement with the state of New York.

In a statement, New York Attorney General Letitia James’ office said the agreement prohibits J&J from promoting opioids through any means. J&J is also now barred from lobbying the products at the federal, state or local level.

J&J stopped marketing its opioid products in the U.S. back in 2015, and as of 2020 has fully discontinued its business of selling them at all here in America.

Part of the settlement also forces J&J to resolve all opioids-related legal claims with allocated payments over the next nine years. The company could also be forced to pay $30 million more in the first year if the state’s executive chamber signs into law new legislation establishing an opioid settlement fund.

Opioid pharmaceuticals have killed at least 500,000 people in the United States over the past several decades. The settlement follows many years of lawsuits filed by states, cities and counties against opioid manufacturers like J&J.

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA